The 340B Drug Pricing Program’s explosive growth continues.
Our exclusive sleuthing reveals that discounted sales hit $16.2 billion in 2016. That’s a 34% increase over the 2015 figure. Consequently, the 340B program accounted for 5.0% of the total U.S. drug market in 2016.
Covered entities are generating billions in untraceable profits from this fast-growing program. Hospitals, which make up the vast majority of 340B purchases, should be required to account clearly for the billions the program provides them.
This growth should make everyone—especially the manufacturers providing the discounts—pay much closer attention to what’s going on.
Read more »
Source: Post feed
